Mobile

A 36 week, multicenter, randomized, double-blind, placebo- controlled, parallel-group study to evaluate the efficacy and safety of aliskiren on the prevention of left ventricular remodeling in high ri...

Mise à jour : Il y a 4 ans
Référence : EUCTR2006-001704-37

A 36 week, multicenter, randomized, double-blind, placebo- controlled, parallel-group study to evaluate the efficacy and safety of aliskiren on the prevention of left ventricular remodeling in high risk post-acute myocardial infarction patients when added to optimized standard therapy

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To demonstrate that aliskiren 300 mg, in addition to standard therapy, has superior efficacy compared to placebo in reducing the primary index of adverse cardiac remodeling (defined as the change in LVESV from baseline to end of study) in patients after high risk acute myocardial infarction.

Critère d'inclusion

  • Post-acute myocardial infarction

Liens